Sage Therapeutics, Inc.
215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 487
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Barry E. Greene | President, CEO & Director | 1.29M | 無 | 1963 |
| Ms. Kimi E. Iguchi CPA | CFO & Treasurer | 665.37k | 144.99k | 1962 |
| Ms. Anne Marie Cook Esq. | Senior VP, General Counsel & Secretary | 711.6k | 無 | 1962 |
| Mr. Christopher Benecchi | Chief Business Officer | 703.76k | 無 | 1972 |
| Dr. Laura Gault M.D., Ph.D. | Chief Medical Officer | 334.08k | 無 | 無 |
| Mr. Matt Lasmanis | Chief Technology & Innovation Officer | 無 | 無 | 無 |
| Mr. Mike Quirk | Chief Scientific Officer | 無 | 無 | 無 |
| Ashley Kaplowitz | Director of Investor Relations | 無 | 無 | 無 |
| Ms. Erin E. Lanciani | Chief People & Experience Officer | 無 | 無 | 1969 |
| Dr. Amy Schacterle Ph.D. | Senior Vice President of R&D Strategy and Business Management | 無 | 無 | 無 |
描述
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月1日 止，Sage Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：7；董事會：7；股東權利：8；現金賠償：9。
